GO
Loading...

Pharmaceuticals

More

  • On the Line: Medco CEO David Snow Thursday, 20 Dec 2007 | 7:47 PM ET

    Cramer knew the company had great earnings visibility, but the chief executive says it's better than the Mad Money host thought.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Genentech, Doctors Now See "Eye To Eye" On Avastin Thursday, 20 Dec 2007 | 4:35 PM ET

    Genentech today has essentially backed down from a proposed crackdown on doctors' use of the cancer drug Avastin instead of the way more expensive Lucentis. The drugs are used to treat age-related macular degeneration (AMD, for short), which is the leading cause of blindness in adults.

  • Masters of Execution: CVS Caremark Wednesday, 19 Dec 2007 | 7:26 PM ET

    This pharmacy used to be number two in the sector. But a smart acquisition helped it take the lead. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.

  • On the Line: BioMarin CEO Jean-Jacques Bienaime Tuesday, 18 Dec 2007 | 12:27 PM ET

    FDA approval for a key drug is making this company some mad money.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Medco Has Long, Healthy Life Ahead Tuesday, 18 Dec 2007 | 12:09 PM ET

    Thanks to some key drugs coming off patent, this pharmacy benefits manager could make $6 billion over the next five years.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Eli Lilly

    Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.

  • Japan to Cut Drug Prices by 5.2% in 2008: Source Tuesday, 18 Dec 2007 | 4:06 AM ET

    Japan will order an average drug price cut of 5.2 percent in its latest drug price review to take effect from next April, a government source said on Tuesday.

  • Heart Disease Still the Leading Cause of Death in US Monday, 17 Dec 2007 | 6:44 PM ET

    The number of Americans dying from cardiovascular disease is going down, but it's still the leading cause of death in the United States. The American Heart Association reports that in 2004 -- the most recent year statistics that are available -- 42,000 fewer people died from cardiovascular disease than in 2003.

  • Cancer Study Shows Over 7.5 Million Deaths in 2007 Monday, 17 Dec 2007 | 1:20 PM ET

    More than seven-and-a-half million people -- or about 20,000 people a day -- will die of cancer this 2007.  That's the sobering new estimate from a first-of-its-kind global study out of the American Cancer Society.

  • Amgen: Is It Down To "The Bone" For Investors? Monday, 17 Dec 2007 | 12:32 PM ET

    Shares of biotech behemoth Amgen are trading at a new intra-day low in the early going this morning after the company announced new data on its developmental osteoporosis drug late Friday. The Phase 3, or late-stage, study was designed to see if the twice-a-year injectable drug strengthened the bones of women with a certain type of breast cancer.

  • Glaxo Cervical Cancer Vaccine Hit by Delay in FDA OK Monday, 17 Dec 2007 | 8:13 AM ET

    GlaxoSmithKline's cervical cancer vaccine Cervarix faces a delay in winning approval in the United States, putting it further behind Merck's rival product Gardasil.

  • Glaxo Drug May Help Shrink Metastatic Brain Tumors Sunday, 16 Dec 2007 | 11:46 AM ET

    Study results show the new oral drug Tykerb from GlaxoSmithKline, combined with chemotherapy, may shrink metastatic brain tumors.

  • The biotech momentum players and the Dendreonites--or Dendreonians--are buzzing about the story we broke on "Power Lunch" Thursday that three members of Congress are asking the House Energy and Commerce Committee to hold a hearing about the Dendreon/Provenge saga. The shares spiked on very heavy volume.

  • Novartis Cuts, While Biogen Idec Cuts And Runs Thursday, 13 Dec 2007 | 4:06 PM ET
    Novartis

    Novartis is the latest company to brand its downsizing, cost-cutting campaign. The Swiss drugmaker is calling its initiative, "Forward". It's not an acronym. So, "Forward" means Novartis is going to try to save $1.6 billion in 2010 and get rid of 2,500 employees. Although I don't think "Forward" is the word which begins with "f" that the affected workers would use to describe the initiative.

  • Congress Asked to Probe Denial of Dendreon Drug Thursday, 13 Dec 2007 | 4:02 PM ET

    Dendreon  shares surged after three members of Congress asked for an investigation of a Food and Drug Administration panel's vote against the pharmaceutical's prostate cancer drug.

  • Biogen Idec Gets No Takeover Bids; Stock Plummets Wednesday, 12 Dec 2007 | 5:05 PM ET
    Carl Icahn

    Biogen Idec said after markets closed Wednesday that it ended its review of strategic options after failing to receive any definitive takeover bids.

  • Pharma's Market with Mike Huckman Wednesday, 12 Dec 2007 | 4:30 PM ET

    Last year one of our producers had the bright idea of assigning each of CNBC's beat reporters a story about seven predictions for their beat for 2007. So, now this year not only do we have to do the 8 for '08 thing for TV, but also for the blog.

  • Dick Clark (Merck CEO) Still Rolling Out Hits For Analysts Wednesday, 12 Dec 2007 | 12:13 PM ET

    The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."

  • Merck: Rolling The Dice With Cholesterol, Diet Drugs Tuesday, 11 Dec 2007 | 2:20 PM ET

    I'm back at Merck HQ in central Jersey for the annual analyst meeting. And I must say that the reception--so far, at least--is much more hospitable and helpful than last year wen things were tense and got a little ugly. A new pr team is in place.